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diabetes researchers who need to classify patients’ renal impairment stage in the 
absence of detailed eGFR data.
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Objectives: Given the lack of specific ICD-9 codes, no definitive method exists for 
identifying irritable bowel syndrome with constipation (IBS-C) and chronic constipa-
tion (CC) patients in administrative claims. This study compared patients identified 
as having IBS-C and CC through claims-based algorithms with modified Rome III 
criteria and patient-reported physician diagnoses. MethOds: Consenting patients 
aged ≥ 18 years identified from the HealthCore Integrated Research Database as 
having IBS-C (≥ 1 IBS claim and ≥ 2 constipation claims or ≥ 1 constipation claim 
and ≥ 1 constipation-related pharmacy claim) or CC (≥ 2 constipation claims ≥ 90 
days apart or ≥ 1 constipation claim and ≥ 1 constipation-related pharmacy claim 
≥ 90 days apart and no IBS claims) completed a cross-sectional survey that included 
questions pertaining to IBS-C/CC symptoms based on modified Rome III criteria and 
patient self-report of IBS-C and CC physician diagnoses to confirm claims-based 
diagnoses. Results: Among 236 claims-based IBS-C patients, 22% met Rome III 
IBS-C criteria and 43% reported being told by a physician they had IBS-C. In addi-
tion, 33% of claims-based IBS-C patients reported being told by a physician they 
had CC. Among 456 claims-based CC patients, 27% met Rome III CC criteria and 39% 
reported being told by a physician they had CC. However, 38% of claims-based CC 
patients met Rome III criteria for IBS-C and 18% reported being told they had IBS-C. 
Patients who did and did not meet Rome III criteria had similar demographic and 
clinical characteristics. cOnclusiOns: A majority of patients identified as having 
IBS-C and CC via claims did not meet Rome III criteria. There was greater agreement 
between claims-based criteria and patient-reported physician diagnoses than Rome 
criteria. Our findings suggest that patients identified through claims may have been 
asymptomatic at the time of the survey, and those identified as CC patients may be 
IBS-C patients who never received an IBS claim.
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Objectives: The measurement properties of three PerfOs [Timed Up-and-Go (TUG), 
4-Step Stair Climb (4SC) and Repeated Chair Stands (RCS, in two versions with arms 
folded, RCS-A, or arm rests, RCS-B)] were evaluated in hip fracture (HF) surgery 
patients. MethOds: Patients were recruited from 11 clinical sites across 6 US states. 
Participants visited sites at designated time points after HF surgery when patient 
reported outcome (PRO) measures, patient- and clinician-reported global concept 
items (GCI), and PerfOs were administered. PerfOs were scored as time (seconds, s) 
to complete each test. PerfO measurement properties evaluated included: reliability 
(inter-rater, test-retest), construct validity (known-groups, convergent/divergent), 
ability to detect change, minimal important difference (MID) and responder defi-
nitions. Results: Data were recruited from 75 patients (mean age 79.64, SD 6.83 
years; 68.0% female) at baseline; from 68 and 66 at visits 2 and 3. Inter-rater (ICCs: 
0.87 to 0.97) and test-retest (ICCs: 0.91-0.95) reliability was excellent across the 
PerfOs. Known-groups validity: Those without an assistive device had quicker mean 
completion times for all PerfOs but the RCS-A. In addition, TUG times were shorter 
for patients with high versus low SF-12 physical component summary (PCS) scores 
(p = .009). Convergent/divergent validity: the TUG, RCS-B, and 4SC demonstrated 
moderate correlations with the SF-12 PCS (rs ranged -0.227 to -0.449), and stronger 
correlations with the individual physical dimensions than the mental component 
(MCS) and dimension scores. Ability to detect change: patients demonstrated sig-
nificant changes in PerfOs from baseline to Visit 2 for the RCS-B (p = 0.030) and 4SC 
(p = 0.034). MIDs ranging from 1.5s (4SC) to 6.0s (TUG) were found. Based on Best 
Cut Points (BCP) of one-point change in clinician GCIs and values of minimal detect-
able change (MDC90), responder definitions between 2.0s (4SC) and 3.5s (TUG) are 
recommended. cOnclusiOns: Overall, the three PerfOs demonstrated adequate 
psychometric properties.
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Objectives: Clinical assessments with a limited time horizon for data collection 
are typical. One example is a (now dated) 10-year study of statin therapy by Pharaoh 
& Hollingsworth, 1996 (P & H). Gray (2011) suggests that this study likely under-
estimates the effect of the intervention by limiting its time horizon. We explore 
this suggestion as a methodological point. MethOds: Using life table methods we 
analyzed one cohort from the P & H publication for which data were reported suffi-
ciently (50-year old men with pre-existing CHD) and compared their limited horizon 
analysis with one which extrapolates until the cohort lives out its life expectancy 
under each treatment alternative. Because of the lack of longer term data, assump-
tions need to be employed in order to extend the results (e.g. the treatment effect 
persists, fully, partially, at different levels, or not at all). Results: We replicated the 
P & H 10-year horizon that indicated a treatment/no treatment mean life expectancy 
difference of 0.071 life years (LYs). Assuming a fully persistent treatment effect over 
lifetimes, this increased to 2.35 LYs in the extrapolation, clearly sufficiently differ-
labeled “new drug,” “old drug,” or “no drug”: non-fatal stroke, non-fatal myocar-
dial infarction (MI), cardiovascular death, minor bleeding, major bleeding, bleeding 
death, and need for therapeutic monitoring. We estimated preference weights and 
maximum acceptable risks. Results: A total of 341 patients and 352 individuals 
from the general population completed the questionnaire. On average, patients per-
ceived a 1% increased risk of a fatal bleeding equivalent to a 2% increase in non-fatal 
MI, a 3% increase in non-fatal stroke, a 3% increase in cardiovascular death, a 6% 
increase in major bleeding, or a 16% increase in minor bleeding. As compared to the 
patients, the general population had similar preferences except that they perceived 
a 3% increase in non-fatal MI or a 13% increase in minor bleeding equivalent to a 
1% increase in risk of bleeding death. Patients were less likely to choose “no drug” 
(odds ratio, 0.72; 95% confidence interval, 0.61- 0.84) or “old drug” (odds ratio, 0.86; 
95% confidence interval, 0.81-0.93) than “new drug.” The general population sample 
was indifferent to the drug labels. cOnclusiOns: Patients and the general popu-
lation had similar relative preferences for anticoagulant treatment outcomes but 
were more likely to choose “new drug,” irrespective of its relative benefits and risks.
PP4
MeasURing tReatMent PRefeRenCes of Patients diagnosed with 
idioPathiC PUlMonaRy fibRosis Using best-woRst sCaling
Camponeschi G.F.1, Bridges J.F.2, Danoff S.K.1, Richardson B.1
1Johns Hopkins University, Baltimore, MD, USA, 2John Hopkins Bloomberg School of Public Health, 
Baltimore, MD, USA
Objectives: Idiopathic pulmonary fibrosis (IPF) is a rare, degenerative disease. 
While recently approved therapies provide hope, research is needed to assess 
the value of treatment benefits and risks. This study sought to develop and test 
a patient-centered survey instrument to value the benefits and risks of IPF thera-
pies. MethOds: Using patient and stakeholder engagement, researchers developed 
a survey instrument for measuring the treatment preferences of IPF patients. This 
led to developing a novel best-worst scaling instrument to assess six treatment 
attributes, each defined across three levels, including lung function, shortness of 
breath, persistent cough, gastrointestinal problems, skin problems and risk of liver 
toxicity. Surveys were completed in person or by mail. Patients were shown 18 treat-
ment profiles, created through a main-effect orthogonal experimental design, and 
asked to identify the best and worst aspect of each treatment. Preference weights 
were estimated using a simple score consisting of the number of times a level was 
chosen as best minus the number of times it was chosen as worst and divided by 
the total number of times the level was shown. Conditional on the level chosen in 
the experiment, attribute importance was estimated by comparing the range of 
scores across each attribute, relative to all such deviations. Results: Thirty-five 
participants completed the survey. The most important attribute preferred was 
effect on lung function (35%), followed by risk of gastrointestinal problems (23%), 
risk of liver toxicity (12%) and impact on persistent cough (11%). Patients estimated 
the least important attributes to be risk of skin problems (9%) and impact on short-
ness of breath (9%). cOnclusiOns: This research demonstrates the merits of a 
community-centered approach to survey instrument development to measure 
preferences and illustrates the value in quantifying preferences. Further research 
is needed to assess the generalizability of these findings and the implications for 
decision making.
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Objectives: The validity of diagnosis/procedure coding for determining the severity 
of renal impairment is unknown. This retrospective, observational study developed 
an administrative claims-based algorithm which classified patients with type 2 
diabetes mellitus (T2DM) into renal impairment stages using estimated glomerular 
filtration rate/1.73 sq M by MDRD equation (eGFR) as the measure for renal func-
tion. MethOds: The data source was U.S. administrative claims collected from 
among a sample of 35,624 patients ≥ 18 years of age who, during the period from 
1/1/2012-12/31/2012, had ≥ 1 laboratory result for eGFR, ≥ 2 medical claims with a 
diagnosis code for T2DM, continuous insurance enrollment, and no medical claims 
with a diagnosis/procedure code for type 1 diabetes, gestational diabetes, or preg-
nancy. The sample was divided into two equal random samples: a test set and 
validation set. Among the test set, four logistic regressions were fit modeling Kidney 
Disease Outcomes Quality Initiative-defined renal impairment stages (eGFR < 15, 
< 30, < 60, and < 90) as a function of age, sex, and 25 binary indicators for the presence 
of medical claims with renal impairment-related diagnosis/procedure codes. From 
each regression, a predicted probability was obtained for the validation set and per-
formance of the algorithm was tested (e.g., by ROC analysis) at varying probability 
cutoff classification thresholds. Results: In the validation set, the percentage of 
patients correctly classified by the test set algorithm using a standard probability 
cutoff= 0.5 was 75.9% for eGFR < 90, 82.1% for < 60, 97.3% < 30, and 99.3% for < 15; 
in the test set, these same percentages deviated by less than 1 percentage point. 
Model C-statistics ranged from 0.79 for eGFR < 90 to 0.89 for eGFR < 15. Sensitivity/
specificity varied considerably by selected probability cutoffs. cOnclusiOns: This 
novel, replicable, administrative claims-based algorithm should prove useful to 
